// App-Quantinova.ai

P-260 : Naïve indirect treatment comparison of PanCO, a pilot study of OncoSil P-32 microparticles combined with gemcitabine + nab-paclitaxel or FOLFIRINOX chemotherapy versus standard-of-care treatment in unresectable locally advanced pancreatic cancer

Researchers

Presenter

  • S. Allerdice

Principal Investigators

  • N. Wilson

  • D. Turner

  • P. McCloud

  • D. Kenny

  • A. Cowley

  • C. Taylor

Medical Centers

  • Health Technology Analysts, Lilyfield, Australia

  • OncoSil Medical Ltd, Sydney, NSW, Australia

  • Adjuvantyx Ltd., Sevenoaks, United Kingdom

  • McCloud Consulting Group, Sydney, Australia

Locations

  • Australia

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Pancreatic cancer

Biomarkers

  • N/A

Drug/Treatment

  • Gemcitabine

  • Paclitaxel

  • FOLFIRINOX

Outcome

  • N/A

Study Design

  • Prospective

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved